2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2777 Immune-inflammatory and nutritional biomarkers predict toxicity and survival after CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Data from the US multiple myeloma immunotherapy consortium

Karen Sweiss, PharmD, Gliceida Galarza Fortuna, MD2, Kyeongmin Kim, PharmD, PhD3, Alexandria Jensen, Phd4, Matias Eugenio Sanchez, MD5, Ana Maria Avila Rodriguez, MD6, Alicia Richards, PHD, MS7, Andrew J. Portuguese, MD8, Lauren C Peres, PhD, MPH9, Saurabh Zanwar, MBBS, MD10, Danai Dima, MD11, Mahmoud R. Gaballa, MD12, Omar Alexis Castaneda Puglianini, MD13, Ariel F. Grajales-Cruz, MD14, Ricardo Daniel Parrondo, MD15, Aimaz Afrough, MD16, Samer Al Hadidi, MD17, Shonali Midha, MD18, Christopher Ferreri, MD19, Cindy Varga, MD20, Francesca Cottini, MD21, Melinda Tan22, Christopher Cahoon, PharmD23, James A Davis, PharmD, BCOP24, Susan Bal, MD25, Sneha Purvey, MD26, Asya Varshavsky, MD27, Lawrence Liu, MD28, Veronika Bachanova, MD, PhD29, Lindsay Fogel, MD30, Lorenzo Gensini, MD31, Sharlene Dong, MD, MS32, Jennifer Ann Kanakry, MD33, Megan M Herr, PhD34, Chenyu Lin, MD35, Omar Nadeem, MD36, Binoy Yohannan, MD37, Timothy O'Brien, MD38, Noa Biran, MD39, Marcus Geer, MD40, Rahul Banerjee, MD, FACP41, Ran Reshef, MD42, Ashley Rosko, MD43, Ciara Louise L Freeman, MD, PhD44, Kenneth H. Shain, MD, PhD45, Nisha Joseph, MD46, Saurabh Chhabra, MD, MBBS47, Larry D Anderson Jr, MD, PhD48, Oren Pasvolsky, MD49, Alissa Visram, MD, MPH50, Hira Mian, MD51, Sarvari V. Yellapragada, MD52, Bruno Almeida Costa, MD53, Tiffany Richards, PhD, NP54, Shebli Atrash, MD55, Peter M Voorhees, MD56, Frederick L. Locke, MD57, Sikander Ailawadhi, MD58, Luciano J. Costa, MD, PhD59, Doug W. Sborov, MD, MS60, Shaji Kumar, MD61, Krina Patel Jr, MD, MSc62, Surbhi Sidana, MD63, Yi Lin Jr, MD, PhD64, Doris K. Hansen, MD65, Lekha Mikkilineni, MD, MA66, Nadine Abdallah I, MD67
1 University of Illinois Chicago, Chicago, Illinois, United States
2 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
3 University of Illinois Chicago, Chicago, Illinois, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 University of Illinois Chicago, Chicago, Illinois, United States
6 University of Illinois Chicago, Chicago, Illinois, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 Mayo Clinic, Jacksonville, Florida, United States
16 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
17 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
20 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
21 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
22 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
23 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
24 Medical University of South Carolina, Charleston, South Carolina, United States
25 University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
26 Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, Virginia, United States
27 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
28 Cedars-Sinai Medical Center, Los Angeles, California, United States
29 University of Minnesota, Minneapolis, Minnesota, United States
30 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
32 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
33 Georgetown University, Washington, District of Columbia, United States
34 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
35 Duke Cancer Institute, Durham, North Carolina, United States
36 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
37 University of Minnesota, Minneapolis, Minnesota, United States
38 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
39 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
40 University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
41 Fred Hutchinson Cancer Center, Seattle, Washington, United States
42 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, United States
43 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
44 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
45 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
46 Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
47 Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
48 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
49 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
50 McMaster University, Hamilton, Ontario, Canada
51 McMaster University, Hamilton, Ontario, Canada
52 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
53 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
54 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
55 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
56 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
57 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
58 Mayo Clinic, Jacksonville, Florida, United States
59 University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
60 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
61 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
62 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
63 Stanford University School of Medicine, Stanford, California, United States
64 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
65 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
66 Stanford University School of Medicine, Stanford, California, United States
67 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States

Introduction: Tools to identify patients at risk for severe toxicities and poor outcomes following CAR-T therapy in RRMM remain limited. CAR-HEMATOTOX is a validated pre-lymphodepletion (LD) score that predicts hematologic toxicity and infections, yet other aspects of fitness including immune dysregulation, nutritional status, and inflammation may also influence toxicity and survival. Readily available biomarkers such as the neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index (PNI, incorporating albumin and absolute lymphocyte count), and ferritin-to-albumin ratio (FAR) broadly reflect these immune, nutritional, and inflammatory pathways and may provide prognostic value. We hypothesized these biomarkers may predict outcomes in patients receiving commercial ciltacabtagene autoleucel (cilta-cel).

Methods: We retrospectively analyzed RRMM patients receiving cilta-cel at 23 US Multiple Myeloma Immunotherapy Consortium centers. NLR, PNI, CAR-HEMATOTOX, and FAR were calculated using routine laboratory parameters obtained pre-LD; malnutrition was defined as PNI <40. Associations with CAR-T–related toxicities, 1-year non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS) were evaluated using multivariable models adjusted for high-risk cytogenetics, extramedullary disease, triple-class refractory status, ECOG performance status, response to bridging therapy, and prior BCMA exposure. Continuous NLR and FAR values were rescaled so that odds ratios (ORs) and hazard ratios (HRs) correspond to 10-unit increases.

Results: Among 1,793 patients, median age was 66 years (range: 29–86), 42.2% female, 14.5% Black, and 84.6% with ECOG 0-1. Median follow-up was 15.5 months. Median pre-LD NLR, FAR, and PNI were 3.48 (range: 0-832), 42.4 (range: 0.930-4830), and 39.0 (range: 16.0-52.0), respectively. Pre-LD, 54.4% of patients met criteria for malnutrition, and 38.9% had high CAR-HEMATOTOX scores.

PNI-defined malnutrition and high CAR-HEMATOTOX scores were associated with higher rates of any-grade ICANS (21.1% vs 10.0% and 22.0% vs 13.6%, respectively; both P<0.001) and severe ICANS (4.3% vs 2.0%, P=0.014 and 5.6% vs 2.0%, P<0.001, respectively). Baseline FAR was significantly higher in patients who developed any-grade ICANS (61.0 vs 39.8, P<0.001) or severe ICANS (145.1 vs 41.3, P=0.004). On multivariable analysis, FAR, CAR-HEMATOTOX, and NLR independently predicted both any-grade (FAR: OR 1.002, 95% CI 1.001-1.003; CAR-HEMATOTOX: OR 1.058, 95% CI 1.011-1.108; NLR: OR 1.014, 95% CI 1.006-1.021) and severe ICANS (FAR: OR 1.0007, 95% CI 1.0003-1.001; CAR-HEMATOTOX: OR 1.03, 95% CI 1.006-1.054; NLR: OR 1.009, 95% CI 1.006-1.013), whereas PNI predicted any-grade ICANS (OR 1.089, 95% CI 1.047-1.124; P<0.001), cranial nerve palsies (P=0.046), and parkinsonism (P=0.02). Elevated FAR also predicted immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) (OR 1.002, 95% CI 1.001-1.003; P<0.001), while higher NLR and CAR-HEMATOTOX predicted post-CAR-T infection (both P<0.001). No biomarker independently predicted CRS.

Elevated FAR (OR 1.0009, 95% CI 1.0004-1.001; P=0.002), PNI-defined malnutrition (OR 1.043, 95% CI 1.014-1.073, P=0.004), and higher NLR (OR 1.01, 95% CI 1.005-1.015; P<0.001) independently predicted increased 1-year NRM, whereas CAR-HEMATOTOX did not retain significance after adjustment. FAR (PFS HR 1.006, 95% CI 1.004-1.008), PNI-defined malnutrition (PFS HR 1.518, 95% CI 1.231-1.871), and high CAR-HEMATOTOX (PFS HR 2.05, 95% CI 1.65-2.55) were each independently associated with inferior PFS and OS (all adj P<0.001), while higher baseline NLR predicted inferior OS (HR 1.049, 95% CI 1.024-1.076, adj P<0.001).

Conclusion: In this large multicenter real-world study of RRMM patients receiving cilta-cel, pre-LD laboratory biomarkers provided complementary prognostic information beyond CAR-HEMATOTOX. FAR was the strongest overall biomarker, independently identifying patients at risk for severe ICANS and IEC-HS, increased NRM and inferior survival, while impaired nutritional status (PNI) was associated with ICANS, increased NRM, and inferior survival. These biomarkers are inexpensive and easily accessible to clinicians; they may enable improved pre-CAR-T risk stratification and identify patients who would benefit from enhanced clinical monitoring and supportive care.

Karen Sweiss, PharmD: No relevant conflicts of interest to declare.